oncology-cancer-therapy-2019-keynote

8 / 11

Page 19
Notes:
allied
academies
Journal of Medical Oncology & Therapeutics | Volume 4
March 18-19, 2019 | London, UK
Oncology & Cancer Therapy
International Conference on
Many epithelial cancers show cell cycle dysfunction
tightly correlated with the overexpression of the
serine/threonine kinase Aurora A (AURKA). Its role in mitotic
progression has been extensively characterised, and evidence
for new AURKA functions emerges. Here, we reveal that
AURKA is located and imported in mitochondria in several
human cancer cell lines. Mitochondrial AURKA impacts on
two organelle functions: mitochondrial dynamics and energy
production. When AURKA is expressed at endogenous levels
during interphase, it induces mitochondrial fragmentation
independently from RALA. Conversely, AURKA enhances
mitochondrial fusion and ATP production when it is over-
expressed. We demonstrate that AURKA directly regulates
mitochondrial functions and that AURKA over-expression
promotes metabolic reprogramming by increasing
mitochondrial interconnectivity. Our work paves the way to
anti-cancer therapeutics based on the simultaneous targeting
of mitochondrial functions and AURKA inhibition.
Speaker Biography
Claude Prigent is a Director of Research CNRS and Head of the Cell Cycle team, IGDR.
He has been elected as an Associate Professor at the University Laval, Quebec, Canada.
After completing his Post-doc in the DNA repair filed under the direction of Thomas
Lindahl at the ICRF in London he has been working on mitosis trying to understand
how this cell cycle stage was control by phosphorylation. He focused his activity on the
Aurora-A kinase and cancer.
e:
Claude Prigent
Université de Rennes, France
The mitotic kinase Aurora kinase A localises to mitochondria to control organelle
dynamics and energy production: Implication for cancer cells overexpressing Aurora-A